Unknown

Dataset Information

0

Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha.


ABSTRACT: Feline infectious peritonitis (FIP) is a fatal inflammatory disease caused by FIP virus infection. Feline tumor necrosis factor (fTNF)-alpha is closely involved in the aggravation of FIP pathology. We previously described the preparation of neutralizing mouse anti-fTNF-alpha monoclonal antibody (mAb 2-4) and clarified its role in the clinical condition of cats with FIP using in vitro systems. However, administration of mouse mAb 2-4 to cat may lead to a production of feline anti-mouse antibodies. In the present study, we prepared a mouse-feline chimeric mAb (chimeric mAb 2-4) by fusing the variable region of mouse mAb 2-4 to the constant region of feline antibody. The chimeric mAb 2-4 was confirmed to have fTNF-alpha neutralization activity. Purified mouse mAb 2-4 and chimeric mAb 2-4 were repeatedly administered to cats, and the changes in the ability to induce feline anti-mouse antibody response were investigated. In the serum of cats treated with mouse mAb 2-4, feline anti-mouse antibody production was induced, and the fTNF-alpha neutralization effect of mouse mAb 2-4 was reduced. In contrast, in cats treated with chimeric mAb 2-4, the feline anti-mouse antibody response was decreased compared to that of mouse mAb 2-4-treated cats.

SUBMITTER: Doki T 

PROVIDER: S-EPMC5059372 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha.

Doki Tomoyoshi T   Takano Tomomi T   Hohdatsu Tsutomu T  

The Journal of veterinary medical science 20160604 9


Feline infectious peritonitis (FIP) is a fatal inflammatory disease caused by FIP virus infection. Feline tumor necrosis factor (fTNF)-alpha is closely involved in the aggravation of FIP pathology. We previously described the preparation of neutralizing mouse anti-fTNF-alpha monoclonal antibody (mAb 2-4) and clarified its role in the clinical condition of cats with FIP using in vitro systems. However, administration of mouse mAb 2-4 to cat may lead to a production of feline anti-mouse antibodies  ...[more]

Similar Datasets

| S-EPMC8524043 | biostudies-literature
| S-EPMC9623662 | biostudies-literature
| S-EPMC6709731 | biostudies-literature
| S-EPMC3318754 | biostudies-literature
2023-03-06 | GSE226619 | GEO
| S-EPMC7714153 | biostudies-literature
| S-EPMC263835 | biostudies-literature
| S-EPMC5694445 | biostudies-literature
| 2154083 | ecrin-mdr-crc
| S-EPMC7051980 | biostudies-literature